Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study
Top Cited Papers
Open Access
- 17 March 2017
- Vol. 356, j1065
- https://doi.org/10.1136/bmj.j1065
Abstract
Objective To prospectively validate the HERDOO2 rule (Hyperpigmentation, Edema, or Redness in either leg; D-dimer level ≥250 μg/L; Obesity with body mass index ≥30; or Older age, ≥65 years), which states that women with none or one of the criteria can safely discontinue anticoagulants after short term treatment. Design Prospective cohort management study. Setting 44 secondary or tertiary care centres in seven countries. Participants Of 3155 consecutive eligible participants with a first unprovoked venous thromboembolism (VTE, proximal leg deep vein thrombosis or pulmonary embolism) who completed 5-12 months of short term anticoagulant treatment, 370 declined to participate, leaving 2785 enrolled participants. 2.3% were lost to follow-up. Interventions Women with none or one of the HERDOO2 criteria were classified as at low risk of recurrent VTE and discontinued anticoagulants (intervention arm), whereas anticoagulant management for high risk women (≥2 HERDOO2 criteria) and men was left to the discretion of the clinicians and patients (observation arm). Main outcome measure Recurrent symptomatic VTE (independently and blindly adjudicated) over one year of follow-up. Results Of 1213 women, 631 (51.3%) were classified as low risk and 591 discontinued oral anticoagulant treatment. In the primary analysis, 17 low risk women who discontinued anticoagulants developed recurrent VTE during 564 patient years of follow-up (3.0% per patient year, 95% confidence interval 1.8% to 4.8%). In 323 high risk women and men who discontinued anticoagulants, 25 had VTE during 309 patient years of follow-up (8.1%, 5.2% to 11.9%), whereas in 1802 high risk women and men who continued anticoagulants 28 had recurrent VTE during 1758 patient years of follow-up (1.6%, 1.1% to 2.3%). Conclusions Women with a first unprovoked VTE event and none or one of the HERDOO2 criteria have a low risk of recurrent VTE and can safely discontinue anticoagulants after completing short term treatment. Trial registration clinicaltrials.gov NCT00967304.Keywords
This publication has 31 references indexed in Scilit:
- Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohortThrombosis Research, 2016
- Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary EmbolismJama-Journal Of The American Medical Association, 2015
- Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysisBMJ, 2013
- Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous ThromboembolismAnnals of Internal Medicine, 2010
- Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort studyThe Lancet, 2003
- Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary EmbolismAnnals of Internal Medicine, 2003
- The Epidemiology of Venous ThromboembolismCirculation, 2003
- Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous ThrombosisNew England Journal of Medicine, 2001
- Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein ThrombosisCirculation, 2001